Immunovant, Inc. (IMVT)
37.36
-0.74
(-1.94%)
USD |
NASDAQ |
Sep 11, 16:00
37.32
-0.04
(-0.11%)
After-Hours: 20:00
Immunovant Enterprise Value : 6.908B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 6.908B |
| September 10, 2026 | 7.061B |
| September 09, 2026 | 7.195B |
| September 08, 2026 | 7.364B |
| September 04, 2026 | 7.298B |
| September 03, 2026 | 7.271B |
| September 02, 2026 | 7.348B |
| September 01, 2026 | 7.432B |
| August 31, 2026 | 7.622B |
| August 28, 2026 | 7.700B |
| August 27, 2026 | 8.241B |
| August 26, 2026 | 8.255B |
| August 25, 2026 | 8.175B |
| August 24, 2026 | 8.138B |
| August 21, 2026 | 8.354B |
| August 20, 2026 | 8.350B |
| August 19, 2026 | 8.476B |
| August 18, 2026 | 8.340B |
| August 17, 2026 | 8.218B |
| August 14, 2026 | 7.828B |
| August 13, 2026 | 7.828B |
| August 12, 2026 | 7.989B |
| August 11, 2026 | 7.645B |
| August 10, 2026 | 7.430B |
| August 07, 2026 | 7.442B |
| Date | Value |
|---|---|
| August 06, 2026 | 7.399B |
| August 05, 2026 | 7.304B |
| August 04, 2026 | 7.321B |
| August 03, 2026 | 7.145B |
| July 31, 2026 | 7.168B |
| July 30, 2026 | 7.346B |
| July 29, 2026 | 7.166B |
| July 28, 2026 | 7.226B |
| July 27, 2026 | 7.471B |
| July 24, 2026 | 7.331B |
| July 23, 2026 | 7.323B |
| July 22, 2026 | 7.257B |
| July 21, 2026 | 7.356B |
| July 20, 2026 | 7.436B |
| July 17, 2026 | 7.506B |
| July 16, 2026 | 7.238B |
| July 15, 2026 | 7.428B |
| July 14, 2026 | 7.199B |
| July 13, 2026 | 7.185B |
| July 10, 2026 | 7.393B |
| July 09, 2026 | 7.678B |
| July 08, 2026 | 7.517B |
| July 07, 2026 | 7.471B |
| July 06, 2026 | 7.164B |
| July 02, 2026 | 7.203B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 53.59B |
| Altimmune, Inc. | 345.63M |
| TG Therapeutics, Inc. | 8.452B |
| Dianthus Therapeutics, Inc. | 4.934B |
| First Tracks Biotherapeutics, Inc. | 1.126B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -153.22M |
| Total Expenses (Quarterly) | 153.22M |
| EPS Diluted (Quarterly) | -0.7454 |
| Earnings Yield | -7.52% |
| Normalized Earnings Yield | -7.520 |